2020
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer
Malani R, Fleisher M, Kumthekar P, Lin X, Omuro A, Groves MD, Lin NU, Melisko M, Lassman AB, Jeyapalan S, Seidman A, Skakodub A, Boire A, DeAngelis LM, Rosenblum M, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. Journal Of Neuro-Oncology 2020, 148: 599-606. PMID: 32506369, PMCID: PMC7438284, DOI: 10.1007/s11060-020-03555-z.Peer-Reviewed Original ResearchConceptsLeptomeningeal metastasesCSF cytologyCSF CTCsCTC enumerationCerebrospinal fluidIT trastuzumabPhase I/II dose escalation trialCentral nervous system compartmentTumor cellsHER2/neu positivityHER2/neu expressionDose-escalation trialHER2-positive cancersIntrathecal trastuzumabEscalation trialRadiographic responseTumor burdenPositive cancersNeu expressionNeu positivityConclusionOur studyPatientsDay 1Epithelial cancersCancer
2018
P05.10 Prospective evaluation of cerebrospinal fluid circulating tumor cells (CSF CTC) in patients with HER2 positive cancers and leptomeningeal metastases receiving treatment with intrathecal trastuzumab
Pentsova E, Malani R, Fleisher M, Lin X, Omuro A, Groves M, Lin N, Melisko M, Lassman A, Jeyapalan S, Boire A, DeAngelis L, Raizer J. P05.10 Prospective evaluation of cerebrospinal fluid circulating tumor cells (CSF CTC) in patients with HER2 positive cancers and leptomeningeal metastases receiving treatment with intrathecal trastuzumab. Neuro-Oncology 2018, 20: iii304-iii304. PMCID: PMC6144227, DOI: 10.1093/neuonc/noy139.336.Peer-Reviewed Original ResearchCSF CTCsLeptomeningeal metastasesCellSearch systemCTC enumerationCSF cytologyTreatment responsePhase I/II dose escalation trialDose-escalation trialPositive CSF cytologyCycles of treatmentHER2-positive cancersCycle 1Number of CTCsIntrathecal trastuzumabIT trastuzumabLM progressionEscalation trialIntrathecal therapyRadiographic responseVentricular reservoirRadiographic worseningProspective evaluationPositive cancersHER2 expressionCerebrospinal fluid
2017
Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors
Lin X, Fleisher M, Rosenblum M, Lin O, Boire A, Briggs S, Bensman Y, Hurtado B, Shagabayeva L, DeAngelis LM, Panageas KS, Omuro A, Pentsova EI. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. Neuro-Oncology 2017, 19: 1248-1254. PMID: 28821205, PMCID: PMC5570249, DOI: 10.1093/neuonc/nox066.Peer-Reviewed Original ResearchConceptsDiagnosis of LMLeptomeningeal metastasesCSF CTCsCSF cytologyEpithelial tumorsMRI findingsOptimal cutoffInstitutional review board-approved prospective studyTumor cellsNegative predictive value 97ROC analysisRare cell capture technologyPositive predictive value 90Positive CSF cytologyCSF of patientsSolid tumor patientsPrevious pilot studyClinical suspicionProspective studyCytology examinationTumor patientsLarge cohortCerebrospinal fluidPatientsStandard MRICerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment.
Malani R, Fleisher M, Lin X, Omuro A, Groves M, Lin N, Melisko M, Lassman A, Jeyapalan S, Briggs S, DeAngelis L, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment. Journal Of Clinical Oncology 2017, 35: 11549-11549. DOI: 10.1200/jco.2017.35.15_suppl.11549.Peer-Reviewed Original ResearchCSF CTCsLeptomeningeal metastasesCellSearch systemTreatment responseCTC enumerationLM progressionCSF cytologyPhase I/II dose escalation trialDose-escalation trialPositive CSF cytologyCycles of treatmentCycle 1IT trastuzumabEscalation trialIntrathecal therapyRadiographic responseVentricular reservoirRadiographic worseningDisease progressionEarly biomarkersCerebrospinal fluidDay 1Colon cancerPotential biomarkersDiagnostic marker
2016
Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid
Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C, Panageas KS, Meng F, Selcuklu SD, Ogilvie S, Distefano N, Shagabayeva L, Rosenblum M, DeAngelis LM, Viale A, Mellinghoff IK, Berger MF. Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. Journal Of Clinical Oncology 2016, 34: 2404-2415. PMID: 27161972, PMCID: PMC4981784, DOI: 10.1200/jco.2016.66.6487.Peer-Reviewed Original ResearchConceptsCentral nervous systemPrimary brain tumorsCerebrospinal fluidCell-free DNACNS involvementBrain tumorsNervous systemCommon malignant primary brain tumorMalignant primary brain tumorRoutine lumbar punctureRelevant genomic alterationsCNS metastasesCNS cancersLumbar punctureCancer-associated genesTumor disseminationHarbored mutationsPatientsTumor evolutionSolid tumorsTumor progressionTumor tissueCancerLiquid biopsyTumors
2015
Prospective validation of cerebrospinal fluid (CSF) circulating tumor cells (CTC) to diagnose leptomeningeal metastasis (LM) from epithelial tumors.
Lin X, Fleisher M, Omuro A, Shagabayeva L, Pentsova E. Prospective validation of cerebrospinal fluid (CSF) circulating tumor cells (CTC) to diagnose leptomeningeal metastasis (LM) from epithelial tumors. Journal Of Clinical Oncology 2015, 33: 2072-2072. DOI: 10.1200/jco.2015.33.15_suppl.2072.Peer-Reviewed Original Research